These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27396372)

  • 1. Immunoglobulin A deficiency following treatment with lamotrigine.
    Maruyama S; Okamoto Y; Toyoshima M; Hanaya R; Kawano Y
    Brain Dev; 2016 Nov; 38(10):947-949. PubMed ID: 27396372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of lamotrigine.
    Richens A
    Epilepsia; 1994; 35 Suppl 5():S37-40. PubMed ID: 8039469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of long-term lamotrigine in epilepsy.
    Mackay FJ; Wilton LV; Pearce GL; Freemantle SN; Mann RD
    Epilepsia; 1997 Aug; 38(8):881-6. PubMed ID: 9579888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgA and IgG2 deficiency associated with zonisamide therapy: a case report.
    Maeoka Y; Hara T; Dejima S; Takeshita K
    Epilepsia; 1997 May; 38(5):611-3. PubMed ID: 9184608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lamotrigine in the adult-onset epilepsy: efficacy and long-term safety].
    Alegre M; Iriarte J; Schlumberger E; Urrestarazu E; Lázaro D; Viteri C
    Neurologia; 2002 Mar; 17(3):136-42. PubMed ID: 11927102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine.
    Svalheim S; Mushtaq U; Mochol M; Luef G; Rauchenzauner M; Frøland SS; Taubøll E
    Acta Neurol Scand Suppl; 2013; (196):11-5. PubMed ID: 23190286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy.
    Baumann RJ; Fakhoury TA; Kustra RP; Vuong A; Hammer AE; Messenheimer JA
    Curr Med Res Opin; 2007 Oct; 23(10):2461-5. PubMed ID: 17727739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Lamotrigine-associated rash.
    Hirsch LJ; Weintraub DB; Buchsbaum R; Spencer HT; Straka T; Hager M; Resor SR
    Epilepsia; 2006 Feb; 47(2):318-22. PubMed ID: 16499755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to replace lamotrigine with valproate.
    Steinhoff BJ
    Epilepsia; 2006 Nov; 47(11):1943-4. PubMed ID: 17116036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexplained spikes in lamotrigine serum concentration: nonlinear elimination?
    Ramey P; Osborn MR; Lowen KM; Reed RC; Abou-Khalil B
    Acta Neurol Scand; 2017 Feb; 135(2):240-246. PubMed ID: 27029219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy.
    Valencia I; Piñol-Ripoll G; Khurana DS; Hardison HH; Kothare SV; Melvin JJ; Marks HG; Legido A
    Eur J Paediatr Neurol; 2009 Mar; 13(2):141-5. PubMed ID: 18585941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy.
    Sander JW; Patsalos PN
    Epilepsy Res; 1992 Oct; 13(1):89-92. PubMed ID: 1478201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of tolerability in elderly patients: changing to lamotrigine therapy.
    Evans BK; Kustra RP; Hammer AE
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):112-9. PubMed ID: 17719513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels.
    Fröscher W; Keller F; Vogt H; Krämer G
    Epileptic Disord; 2002 Mar; 4(1):49-56. PubMed ID: 11967180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human safety of lamotrigine.
    Betts T; Goodwin G; Withers RM; Yuen AW
    Epilepsia; 1991; 32 Suppl 2():S17-21. PubMed ID: 1837776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients.
    Zeng K; Wang X; Xi Z; Yan Y
    Clin Neurol Neurosurg; 2010 May; 112(4):291-5. PubMed ID: 20071075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a lamotrigine withdrawal syndrome?
    Gelisse P; Kissani N; Crespel A; Jafari H; Baldy-Moulinier M
    Acta Neurol Scand; 2002 Mar; 105(3):232-4. PubMed ID: 11886370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
    Tompson DJ; Ali I; Oliver-Willwong R; Job S; Zhu L; Lemme F; Hammer AE; Vuong A; Messenheimer JA
    Epilepsia; 2008 Mar; 49(3):410-7. PubMed ID: 17825077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting.
    Helmstaedter C; Witt JA
    Epilepsy Behav; 2013 Feb; 26(2):182-7. PubMed ID: 23318473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature.
    Brandt C; Fueratsch N; Boehme V; Kramme C; Pieridou M; Villagran A; Woermann F; Pohlmann-Eden B
    Epilepsy Behav; 2007 Aug; 11(1):133-9. PubMed ID: 17485241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.